Dr. Huang’s research work began with his Ph.D. degree in Organic Chemistry at Peking University in China in 1996. He studied the enantio-selective reaction of 2H-1, 5-benzodiazepine with diazoacetate to synthesize novel heterocyclic [6,7,3] ring compounds. The highest enantiomeric excess of the products was 85%. He then worked for two years as a Research Scientist at the Institute of Chemistry, the Chinese Academy of Science. This work focused on the design and synthesis of heterocyclic compounds. In 1998, he came to the United States and worked as a Research Associate at the Department of Chemistry, at Ohio State University until 2002. He synthesized novel intramolecularly hydrogen bonded dendrons and dendrimers which could, for the first time, achieve dendrimer secondary conformational orders.
In 2002, Dr. Huang joined a newly formed biotechnology company, Dendritic Nanotechnologies, located in Mount Pleasant, Michigan as a Research Scientist. At Dendritic Nanotechnologies, he has been involved in several projects, including new dendrimer development, PAMAM dendrimer modification, drug delivery, quantum dots stabilization, as well as MRI contrast agents synthesis and conjugation. He served as project leader on research projects such as development of dendritic architectures for biological and electronic nano-device construction (an Army Research Lab project). He also worked on the development of pharmaceutical grade Priostar dendrimers. At Dendritic Nanotechnologies, he was promoted to Senior Scientist in April, 2005. His work there resulted in the publication of six out of a total of 13 peer-reviewed papers as well as seven patents.
Baohua Huang, Ph.D. joined the Division of Allergy, Department of Internal Medicine and the Michigan Nanotechnology Institute for Medicine and Biological Sciences as a Research Investigator in June 4, 2007. Dr. Huang works on poly(amidoamine) dendrimer synthesis for targeted cancer drug delivery systems that are formed from dendrimers which are nanometer size polymers that serve as inert scaffolding. Targeting vectors are attached to the dendrimers and serve as precision guidance systems that direct the system to sites of disease, while bypassing healthy tissue. He also works on a project that uses dendrimers and linkers as a drug delivery/release platform for improved delivery of analgesics on the battlefield and other pain management applications.